Pelthos Therapeutics (PTHS) EBITDA Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly EBITDA Margin of 72.74% for Q4 2025, up 98.61% quarter-over-quarter from 5225.17% in Q3 2025.

Pelthos Therapeutics (PTHS) EBITDA Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 72.74% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Pelthos Therapeutics	96.56 Mn	72.00 Mn	21.23 Mn	-114.72%

Download Data